Graphite Bio Inc
NASDAQ:LENZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Axial Retailing Inc
TSE:8255
|
JP |
|
F
|
FatPipe Inc
NASDAQ:FATN
|
US |
|
MediciNova Inc
NASDAQ:MNOV
|
US |
|
N
|
Nippon Television Holdings Inc
TSE:9404
|
JP |
|
N
|
Next PLC
F:NXG
|
UK |
Graphite Bio Inc
Research & Development
Graphite Bio Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Graphite Bio Inc
NASDAQ:LENZ
|
Research & Development
-$29.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Graphite Bio Inc
Glance View
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
See Also
What is Graphite Bio Inc's Research & Development?
Research & Development
-29.8m
USD
Based on the financial report for Dec 31, 2024, Graphite Bio Inc's Research & Development amounts to -29.8m USD.
What is Graphite Bio Inc's Research & Development growth rate?
Research & Development CAGR 3Y
8%
Over the last year, the Research & Development growth was 7%. The average annual Research & Development growth rates for Graphite Bio Inc have been 8% over the past three years .
